Acadia Pharma (ACAD) Misses Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Acadia Pharma (ACAD) Misses Q1 EPS by 3c

ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results

May 5, 2016 4:07 PM EDT

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2016.

We are very excited about the recent FDA approval of NUPLAZID, the first and only drug approved for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis, said Steve Davis, ACADIAs President and Chief Executive Officer. Parkinsons psychosis tends to strike in the more advanced stages of... More